Abstract:Clinical trials of investigational agents in systemic lupus erythematosus (SLE) have focused on targeting dysregulated B and T cells; however, recent translational research findings of the importance of the dysregulation of the innate immune system in SLE have led to clinical trials that target interferon. Three biologics that target type I interferons have been tested for their efficacy and safety in active SLE patients; these phase II trials have tested the hypothesis that down-regulation of interferon-regulated gene expression (the interferon signature) lessen the clinical burden of SLE. Rontalizumab, an anti-interferon-α monoclonal antibody, was studied in patients who had discontinued immunosuppressants. This study failed to show efficacy as assessed by both two outcome assessments; however, in low interferon signature patients, response was higher and corticosteroid usage was less in rontalizumab-treated patients. Sifalimumab, another anti-interferon-α monoclonal antibody, was studied in patients who remained on standard of care therapy. This study showed significantly better efficacy in patients treated with two sifalimumab dosages; significant differences were seen in the high interferon signature group. In a similar design and in a similar population as the sifalimumab study, anifrolumab, a monoclonal antibody that binds to a type I interferon receptor, was studied in patients who remained on standard of care therapy. In this study, one dosage group demonstrated efficacy and statistically significant effects were achieved in both tested dosage groups with secondary end points. Oral corticosteroid reduction to ≤7.5 mg daily was achieved in one of the tested dosage groups and organ-specific outcomes were significantly improved in that same group. For all studies, no significant differences in serious adverse effects were seen; although, herpes zoster infections were increased in sifalimumab- and anifrolumab-treated patients and influenza rates were increased in anifrolumab-treated patients. Anifrolumab is currently in pivotal phase III studies. Data appear to support the concept that targeting type I interferon in SLE patients associates with clinical efficacy and safety. Further data are forthcoming from ongoing phase III clinical trials of anifrolumab. Other drug development efforts should be considered that target plasmacytoid dendritic cells and toll like receptors given the effects these components have on interferon production.

Structural Basis for Inhibition of Interferon Alpha Signaling Pathway and Its Therapeutic Potential in SLE Patients

Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus

Targeting interferons and their pathways in systemic lupus erythematosus

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab

Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?

Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients

Interferon Inhibition in SLE: From Bench to Bedside

Protein Interaction for an Interferon-Inducible Systemic Lupus Associated Gene, IFIT1

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned

Inhibition of IRF5 hyperactivation protects from lupus onset and severity

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

Dysregulation of Type I Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?

EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice

Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus

Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon-α Receptor Antibody.

Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies

[Using GST-tag to Capture Protein Interaction of an Interferon-Inducible Systemic Lupus Associated Gene, IFIT1].

Ligation of CD180 Inhibits IFN-α Signaling in a Lyn-PI3K-BTK-dependent Manner in B Cells

Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE

The Expression of Interferon-Αin the Peripheral Blood and Correlation with Disease Activity in Systemic Lupus Erythematosus Patients

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus